You Need to Buy HEXO (TSX:HEXO) Today!

HEXO Corp’s (TSX:HEXO)(NYSE:HEXO) stock price has tumbled this year. Is this a good RRSP or TFSA stock?

| More on:

Generally speaking, I am not big on recommending stocks in the marijuana industry.

The reason for this is because the marijuana industry is so inflated, I find it hard to find a company that has a strong underlying business and a competitive advantage in the crowded industry.

That said, HEXO (TSX:HEXO)(NYSE:HEXO) is a game changer in the marijuana industry. For those of you unfamiliar with the company, it is a consumer packaged goods cannabis company specializing in ease-of-use marijuana products.

Its brands include the eponymously named HEXO, the sublingual mist product line Elixir, the fine-milled cannabis line Decarb and the typical dried cannabis. On a purely revenue basis, the company is the sixth-largest marijuana company in North America.

Its reputation has helped the company secure a $65 million syndicated credit facility with CIBC and BMO, which gives credibility to HEXO.

The reason why HEXO is worth your investment is due to its price point and its increasing revenues.

Attractive price point

Let’s face it, at $32.85 a share, Canopy Growth’s stock prices out a lot of investors. If you were to buy just 100 shares of Canopy Growth, you would be paying over $3,000!

I don’t know about you, but for investors like me, that’s a significant chunk of my portfolio. Unlike Canopy Growth, HEXO is priced at $5.46 a share, which means 100 shares will only set you back $546.

In the investing world, it has been said that returns should be based on percentages — not values; however, I beg to differ.

Think of it this way: if you’ve put $3,285 into Canopy Growth (essentially buying 100 shares) and it goes down by 10%, you’ve lost $329.

If you purchased 100 shares of HEXO for $546 and it declined 10%, you would lose $55. As you can see, the amount of risk you’re exposed to at HEXO’s price point is much less than Canopy Growth. At the end of the day, both stocks are in the marijuana industry, which means the volatility for the two would be comparable, but at least with HEXO, you’ll still have money left in your portfolio.

Steadily increasing revenues

I was pleasantly surprised to see HEXO’s revenues increasing since fiscal 2016.

From fiscal 2016 to fiscal 2018, its revenues have grown from $1.87 million to $4.93 million for a compounded annual growth rate of 38.14%!

Given that Canopy Growth lost $1.2 billion in one quarter this year, HEXO is definitely showing it’s healthier and better managed than its competitor.

Admittedly, the company took a net loss of $23 million in fiscal 2018, which is not ideal; however, the company’s competitive advantage by targeting the ease-of-use market puts it several steps ahead of Canopy Growth, even with its net loss.

Summary

Investors have definitely overlooked HEXO during the marijuana craze partially due to its comparatively small market capitalization at $1.4 billion.

This is advantageous for people like you who are reading this article, as HEXO is currently trading at an attractive price point, and it is showing signs of steady revenue growth.

Both these traits coupled with its focus on the ease-of-use market put HEXO in a strong position, where it can grow and deliver solid returns to investors.

If you liked this article, click the link below for exclusive insight.

Fool contributor Chen Liu has no position in any of the stocks mentioned.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »